UROPLASTY INC

Operating margin

−21.6%

Net margin

−21.8%

Return on equity

−40.5%

Return on assets

−30.9%

Return on capital (ROCE)

−38.1%

Liabilities / assets

23.6%

Debt / equity

0.31×

Book value / share

$0.60

Revenue growth (YoY)

9.6%

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

-2.20distress

Accruals / assets

−14.2%clean

Beneish M-Score

-3.50normal

Piotroski F-Score

2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Shareholder vote · Regulation FD disclosureMar 31, 2015
• Other material eventMar 10, 2015
• Other material eventMar 3, 2015
• Other material eventJan 27, 2015
• Results of operationsJan 22, 2015
• Entered a material agreement · Other material eventDec 22, 2014
• Director / officer changeOct 24, 2014
• Results of operationsOct 23, 2014

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.